Protease-deleted adenovirus as an alternative for replication-competent adenovirus vector

被引:0
|
作者
Elahi, S. Mehdy [1 ,3 ]
Nazemi-Moghaddam, Nazila [1 ]
Gilbert, Renald [1 ,2 ]
机构
[1] Natl Res Council Canada, Dept Prod Platforms & Analyt, Bldg Montreal, Montreal, PQ, Canada
[2] McGill Univ, Dept Bioengn, Montreal, PQ, Canada
[3] Natl Res Council Canada, Bldg Montreal,6100 Ave Royalmount, Montreal, PQ H4P 2R2, Canada
关键词
Protease -deleted adenovirus; Single -cycle adenovirus vector; Replication -competent adenovirus vector; Replication -defective adenovirus; Adenovirus E4 region; ONCOLYTIC ADENOVIRUS; TRANSGENE EXPRESSION; IMMUNE-RESPONSES; GENE-EXPRESSION; VIRUS ENTRY; E3; REGION; GENERATION; GENOME; CELLS; VACCINATION;
D O I
10.1016/j.virol.2023.07.009
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
For cancer therapy and vaccination an amplified expression of the therapeutic gene is desired. Previously, we have developed a single-cycle adenovirus vector (SC-AdV) by deleting the adenovirus protease (PS) gene. In order to keep the E1 region intact within the PS-deleted adenoviruses, we examined the insertion of two transgenes under the control of a constitutive or inducible promoters. These were inserted between E4 and the right inverted terminal repeat in a wide variety of backbones with various combinations of PS, E3 and E4 deletion. Our data showed that PS-deleted adenoviruses, expressed transgenes as strongly as replicationcompetent AdVs in HEK293A and a variant of HeLa cells. In a head-to-head comparison in four human cell lines, we demonstrated that SC-AdV, was comparable for transgene expression efficacy with its replicationcompetent counterpart. However, the SC-AdV expresses its transgene 10 to 16,000 times higher than its replication-defective counterpart.
引用
收藏
页码:67 / 75
页数:9
相关论文
共 50 条
  • [1] Construction of recombinant adenovirus-5 vector to prevent replication-competent adenovirus occurrence
    Xie, Wenbo
    Yuan, Yifei
    Liu, Bo
    Liang, Min
    ACTA VIROLOGICA, 2023, 67 : 1 - 2
  • [2] A fully replication-competent adenovirus vector with enhanced oncolytic properties
    Toth, K.
    Kuppuswamy, M.
    Shashkova, E. V.
    Spencer, J. F.
    Wold, W. S. M.
    CANCER GENE THERAPY, 2010, 17 (11) : 761 - 770
  • [3] A fully replication-competent adenovirus vector with enhanced oncolytic properties
    K Toth
    M Kuppuswamy
    E V Shashkova
    J F Spencer
    W S M Wold
    Cancer Gene Therapy, 2010, 17 : 761 - 770
  • [4] Switching a Replication-Defective Adenoviral Vector into a Replication-Competent, Oncolytic Adenovirus
    Nakashima, Hiroshi
    Chiocca, E. Antonio
    JOURNAL OF VIROLOGY, 2014, 88 (01) : 345 - 353
  • [5] Rapid Detection of Replication-Competent Adenovirus (RCA) in Adenoviral Vector Material
    Fun, Axel
    MOLECULAR THERAPY, 2022, 30 (04) : 200 - 200
  • [6] No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants
    Lee, Dongwoo
    Liu, Jida
    Junn, Hyun Jung
    Lee, Eun-Joo
    Jeong, Kyu-Shik
    Seol, Dai-Wu
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2019, 51 (10): : 1 - 18
  • [7] No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants
    Dongwoo Lee
    Jida Liu
    Hyun Jung Junn
    Eun-Joo Lee
    Kyu-Shik Jeong
    Dai-Wu Seol
    Experimental & Molecular Medicine, 2019, 51 : 1 - 18
  • [8] Oncolytic virotherapy of meningiomas in vitro with replication-competent adenovirus
    Grill, J
    Lamfers, MLM
    van Beusechem, VW
    van der Valk, P
    Huisman, A
    Sminia, P
    Alemany, R
    Curiel, DT
    Vandertop, WP
    Gerritsen, WR
    Dirven, CMF
    NEUROSURGERY, 2005, 56 (01) : 146 - 153
  • [9] A novel attenuated replication-competent adenovirus for melanoma therapy
    I Peter
    C Graf
    R Dummer
    W Schaffner
    U F Greber
    S Hemmi
    Gene Therapy, 2003, 10 : 530 - 539
  • [10] Development of replication-competent adenovirus based vaccine vectors
    P Abbink
    LF Maxfield
    DH Barouch
    Retrovirology, 9